ID   Hs 294T
AC   CVCL_0331
SY   HS-294T; Hs-294T; HS-294-T; HS-294; Hs294T; HS294T; Hs294; HS294
DR   BTO; BTO:0003467
DR   CLO; CLO_0003917
DR   EFO; EFO_0006585
DR   MCCL; MCC:0000227
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-140
DR   BioGRID_ORCS_Cell_line; 178
DR   BioSample; SAMN03471454
DR   BioSample; SAMN10988350
DR   cancercelllines; CVCL_0331
DR   Cell_Model_Passport; SIDM00800
DR   CGH-DB; 9319-4
DR   ChEMBL-Cells; CHEMBL4523539
DR   ChEMBL-Targets; CHEMBL4523570
DR   Cosmic; 905232
DR   Cosmic; 933000
DR   DepMap; ACH-000014
DR   EGA; EGAS00001000610
DR   GEO; GSE52246
DR   GEO; GSM206511
DR   GEO; GSM274685
DR   GEO; GSM887096
DR   GEO; GSM888167
DR   IARC_TP53; 30047
DR   LiGeA; CCLE_572
DR   PharmacoDB; Hs294T_573_2019
DR   Progenetix; CVCL_0331
DR   PubChem_Cell_line; CVCL_0331
DR   Wikidata; Q54895578
RX   PubMed=265522;
RX   PubMed=327080;
RX   PubMed=375235;
RX   PubMed=478563;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=8755562;
RX   PubMed=11414198;
RX   PubMed=15467732;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=39175042;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   HLA typing: A*01:01,25:01; B*07:02,08:01; C*07:02,07:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15467732; DepMap=ACH-000014).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.39%; East Asian, North=0%; East Asian, South=0%; South Asian=0.34%; European, North=72.19%; European, South=27.07% (PubMed=30894373).
CC   Misspelling: HTB-140; Note=Based on the ATCC catalog number.
CC   Misspelling: HTB140; Note=Based on the ATCC catalog number.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ATCC=HTB-140; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D18S51: 13,17
ST   D19S433: 14,14.2
ST   D21S11: 30
ST   D2S1338: 17,24
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 10
ST   D8S1179: 13,14 (ATCC=HTB-140)
ST   D8S1179: 14 (PubMed=25877200)
ST   FGA: 23,24
ST   Penta D: 13
ST   Penta E: 7,10
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 44
//
RX   PubMed=265522; DOI=10.1073/pnas.74.2.565; PMCID=PMC392331;
RA   Fabricant R.N., De Larco J.E., Todaro G.J.;
RT   "Nerve growth factor receptors on human melanoma cells in culture.";
RL   Proc. Natl. Acad. Sci. U.S.A. 74:565-569(1977).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=375235; DOI=10.1073/pnas.76.3.1288; PMCID=PMC383236;
RA   Sherwin S.A., Sliski A.H., Todaro G.J.;
RT   "Human melanoma cells have both nerve growth factor and nerve growth
RT   factor-specific receptors on their cell surfaces.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
//
RX   PubMed=478563; DOI=10.1007/BF02616140;
RA   Creasey A.A., Smith H.S., Hackett A.J., Fukuyama K., Epstein W.L.,
RA   Madin S.H.;
RT   "Biological properties of human melanoma cells in culture.";
RL   In Vitro 15:342-350(1979).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=8755562; DOI=10.1073/pnas.93.15.7832; PMCID=PMC38834;
RA   Liu D.-C., Pearlman E., Diaconu E., Guo K., Mori H., Haqqi T.,
RA   Markowitz S.D., Willson J.K.V., Sy M.-S.;
RT   "Expression of hyaluronidase by tumor cells induces angiogenesis in
RT   vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:7832-7837(1996).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=39175042; DOI=10.1186/s12964-024-01788-3; PMCID=PMC11342534;
RA   Kot M., Simiczyjew A., Wadzynska J., Zietek M., Matkowski R.A.,
RA   Nowak D.;
RT   "Characterization of two melanoma cell lines resistant to BRAF/MEK
RT   inhibitors (vemurafenib and cobimetinib).";
RL   Cell Commun. Signal. 22:410.1-410.21(2024).
//